Potential Role for Pulmonary Surfactant in Lung Transplantation

  • Fred Possmayer
  • Richard J. Novick
  • Ruud A. W. Veldhuizen
  • John Lee
  • David Bjarneson
  • Jim F. Lewis
Part of the NATO ASI Series book series (NSSA, volume 297)


Since its introduction in 1954 by Murray and colleagues, allotransplantation has greatly improved the quality, as well as the duration of life for those involved.1 The discovery of immunosuppressant drugs advanced long term efficacy of transplantation and led to a further improvement in the quality of life. Unfortunately, maximal potential benefits have never been achieved. As with a number of other organs, particularly kidneys, livers and hearts, there are lengthy waiting lists for suitable lungs. This lack of sufficient organs results, not only from the limited number of donors, but in part because many of the lungs available for transplant are judged unsuitable, due to edema, aspiration or contusion. The short period over which lungs remain clinically viable, presently 6–8 hours, also limits the availability of these organs. Furthermore, the practice of maintaining brain-damaged potential organ donors on respirators using high oxygen levels and vigorous mechanical ventilation contributes to the paucity of available lungs.


Acute Lung Injury Lung Transplantation Left Lung Pulmonary Surfactant Exogenous Surfactant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R.P. Lanza, D.K.C. Cooper, and W.L. Chick, Xenotransplantation, Sci Am. 277:54 (1997).PubMedCrossRefGoogle Scholar
  2. 2.
    F. Possmayer, Physicochemical aspects of pulmonary surfactant, in: Fetal and Neonatal Physiology, R.A. Poulin and W.W. Fox, eds., WB Saunders Company, Boca Raton (1997). (in press)Google Scholar
  3. 3.
    R.J. King and J.A. Clements, Surface active materials from dog lung. II. Composition and physiological correlations, A m J Phys. 223:715 (1972).Google Scholar
  4. 4.
    R.A.W. Veldhuizen, J. Lee, D. Sandler, W. Hull, J.A. Whitsett, F. Possmayer and R.J. Novick, Alterations in pulmonary surfactant composition and activity after experimental lung transplantation, Am Rev Respir Dis. 148:208 (1993).PubMedGoogle Scholar
  5. 5.
    L.A.J.M. Creuwels, L.M.G. van Golde and H.P. Haagsman, The Pulmonary surfactant system: biochemical and clinical aspects, Lung. 175:1 (1997).PubMedCrossRefGoogle Scholar
  6. 6.
    J. Johansson, and T. Curstedt, Molecular structures and interactions of pulmonary surfactant components, Eur J Biochem. 244:675 (1997).PubMedCrossRefGoogle Scholar
  7. 7.
    L.M.G. van Golde, J.J. Batenburg and B. Robertson, The pulmonary surfactant system, Int Union Physiol SciJ/Am Physiol Soc. 9:13 (1994).Google Scholar
  8. 8.
    N.J. Gross, Extracellular metabolism of pulmonary surfactant: the role of a new serine protease, Annu Rev Physiol. 57:135 (1995).PubMedCrossRefGoogle Scholar
  9. 9.
    J.F. Lewis and A.H. Jobe, Surfactant and the adult respiratory distress syndrome, Am Rev Respir Dis. 147:218 (1993).PubMedGoogle Scholar
  10. 10.
    J.F. Lewis and R.A.W. Veldhuizen, Factors influencing efficacy of exogenous surfactant in acute lung injury, Biol Neonate. 67: 48 (1995).PubMedCrossRefGoogle Scholar
  11. 11.
    U.S. Yu, N. Smith, P.G.R. Harding and F. Possmayer, Bovine pulmonary surfactant: Chemical composition and physical properties, Lipids. 18:522 (1983).PubMedCrossRefGoogle Scholar
  12. 12.
    J.F. Lewis, J.S. Dhillon, R. Singh, C.C. Johnson and T.C. Frewen, Exogenous surfactant therapy for pediatric patients with the acute respiratory distress syndrome, Can Resp J. 4:21 (1997).Google Scholar
  13. 13.
    R.J. Novick, R.A.W. Veldhuizen, F. Possmayer, J. Lee, D. Sandler, and J.F. Lewis, Exogenous surfactant therapy in thirty-eight hour lung graft preservation for transplantation, J Thorac Cardiovasc Surg. 108:259 (1994).Google Scholar
  14. 14.
    R.J. Novick, J. MacDonald, R.A.W. Veldhuizen, J. Duplan, L. Denning, F. Possmayer, A. Gilpin, L.J. Yao, D. Bjarneson and J.F. Lewis., Evaluation of surfactant treatment strategies after prolonged graft storage in lung transplantation, Am J Respir Crit Care Med. 154:98 (1996).PubMedGoogle Scholar
  15. 15.
    R.J. Novick, A.A. Gilpin, K.E. Gehman, LS. Ali, R.A.W. Veldhuizen, J. Duplan, L. Denning, F. Possmayer, D. Bjarneson and J.F. Lewis, Mitigation of injury in canine lung grafts by exogenous surfactant therapy, J Thorac Cardio Vase Surg. 113:342 (1997).CrossRefGoogle Scholar
  16. 16.
    D.S. Strayer, E. Herting, B. Sun and B. Robertson, Antibody to surfactant protein A increases sensitivity of pulmonary surfactant inactivation by fibrinogen in vivo, Am J Resp Crit Care Med. 153:1116 (1996).PubMedGoogle Scholar
  17. 17.
    K. Yukitake, C.L. Brown, M.A. Schlueter, J.A. Clements and S. Hawgood, Surfactant apoprotein A modifies the inhibitory effect of plasma proteins on surfactant activity in vivo, Pediatr Res. 37:21 (1995).PubMedCrossRefGoogle Scholar
  18. 18.
    M.E. Erasmus, A.H. Petersen, G. Hofstede, H.P. Haagsman, S.B. Oetomo and J. Prop Surfactant treatment before reperfusion improves the immediate function of lung transplants in rats, Am J Respir Crit Care Med. 153:665 (1996).PubMedGoogle Scholar
  19. 19.
    M.E. Erasmus, A.H. Petersen, S.B. Oetomo and J. Prop, The function of surfactant is impaired during the reimplantation response in rat lung transplants, J Heart Lung Transplan. 13:791 (1994).Google Scholar
  20. 20.
    Novick, R.J., Gehman, K.E., Ali, LS., and Lee, J., 1996 Lung preservation — the importance of endothelial and alveolar type II cell integrity, Ann Thorac Surg. 62:302.Google Scholar
  21. 21.
    A. Günther, I. Friedrich, F.H. Splittgerber, J. Börgermann, M. Brinkmann, R. Schmidt, M. Yabut, C. Reidemeister and W. Seeger, Attenuation of reperfusion-induced alteration of surfactant properties by application of bovine surfactant extract in a model of single lung transplantation, Am J Resp Crit Care Med. 155: A214. (1991).Google Scholar

Copyright information

© Plenum Press, New York 1998

Authors and Affiliations

  • Fred Possmayer
    • 1
  • Richard J. Novick
    • 2
  • Ruud A. W. Veldhuizen
    • 3
  • John Lee
    • 2
  • David Bjarneson
    • 4
  • Jim F. Lewis
    • 3
  1. 1.Departments of Obstetrics & Gynaecology and Biochemistry and MRC Group in Fetal and Neonatal Health and DevelopmentSan DiegoUSA
  2. 2.Division of Cardiovascular/Thoracic SurgeryDepartment of MedicineSan DiegoUSA
  3. 3.Division of RespirologyDepartment of Medicine The University of Western OntarioLondonCanada
  4. 4.BLES Biochemicals, Inc.LondonCanada

Personalised recommendations